Frontlight ResearchEarly access
Taking peoplePhase 2/3
Tau PET brain scans in memory clinics for mild cognitive impairment and dementia
Tests tau PET scans as a diagnostic tool for people with memory problems.
Key facts
- Who runs it
- Amsterdam UMC
- Where
- Netherlands6 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- TAP-TAU
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 360 people, planned
- Started
- 10 Oct 2024
- Expected to end
- 1 Dec 2026
- Type of study
- Interventional
- Record updated
- 18 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for memory clinic patients with mild memory or thinking problems or mild dementia. Their diagnosis must still be unclear after routine tests, and Alzheimer's disease must be one possible cause.
- Age
- The criteria say 50 years or older; the record's minimum age field says 65 Years.
- Sex
- All sexes can join.
- Disease stage
- Early stage (mild cognitive impairment, CDR score 0.5) or mild dementia (CDR score 1). The doctors must be less than 85% sure of the diagnosis. Reasons can be suspected mixed causes, unusual symptoms, or unclear results from other tests like MRI or spinal fluid (CSF).
- Earlier treatment
- People must have finished routine work-up, with at least basic memory tests and an MRI scan with a 3DT1 sequence. Tau PET participants cannot join if they were ever treated with an anti-amyloid drug or tau agent.
Main reasons for not taking part
- Normal memory and thinking (CDR 0) or advanced dementia (CDR above 1).
- Major stroke, mass or other brain changes on MRI that could affect symptoms or the PET scan.
- Other serious diseases of the heart, blood, liver, kidneys, lungs, mind or other organs, as judged by the lead researcher.
- For tau PET: pregnancy, breastfeeding, no reliable birth control, or a severe drug allergy.
- For tau PET: a recent radioactive tracer injection, or yearly research radiation above 11.3 mSv for females and 15.3 mSv for males.
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Patients 50 years or older
- Prodromal (i.e. MCI) stage, in which individuals have subjective and/or objective cognitive impairment and a CDR score of 0.5 or mild dementia stage, in which individuals have a CDR score of 1
- Completed routine work-up including at least basic cognitive screening tests and MRI scanning with a 3DT1 sequence
- After routine dementia screening, there is substantial diagnostic uncertainty (<85%) due to i) suspicion of mixed pathology, ii) presence of an atypical clinical presentation, and/or iii) conflicting/inconclusive information from other diagnostic tests like MRI or CSF. AD is in the differential diagnosis
- Subjects must, in the opinion of the attending neurologist be able to tolerate study procedures (only for the tau PET participants) and be competent to make a well-informed decision to participate in this study
Who cannot take part
- Has ever been treated with an anti-amyloid drug or tau agent (only for tau PET participants)
- Has been injected with a previously administered radiopharmaceutical within 6 terminal half-lives or when total yearly radiation exposure for research exceeds 11.3 mSv for females and 15.3 mSv for males. (only for tau PET participants)
- Cognitively normal (defined as no objective cognitive deficits at neuropsychological testing and a Clinical Dementia rating scale (CDR) score of 0) or advanced dementia stage (defined as CDR > 1)
- Has evidence of structural abnormalities such as major stroke or mass on MRI that is likely to interfere with the clinical presentation and/or interpretation of PET scan
- Has a relevant history of severe drug allergy or hypersensitivity. Relevant severe drug allergies should be determined by the locally appointed coordinating researcher (only for tau PET participants)
- History of any clinically significant cardiovascular, endocrinology, hematologic, hepatobiliary, immunologic, metabolic, urologic, pulmonary, neurologic (with the exception of AD), psychiatric, renal or other major disease, as determined by the principal investigator
- Is a woman of childbearing potential who is not surgically sterile, not refraining from sexual activity or not using reliable methods for contraception. Women of childbearing potential must confirm not to be pregnant or breast feeding at screening; (only for tau PET participants)
- Is a member of the study team, an employee of the department of Radiology and Nuclear medicine or the department of Neurology in any of the sites or is related to an employee of the department of Radiology and Nuclear medicine or the department of Neurology in any of the sites
This trial is currently available in Netherlands.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To assess the value of tau PET as a diagnostic tool in clinical practice in order to improve diagnostic accuracy, patient management and patient wellbeing.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- The clinical value of tau PET in the memory clinic (TAP-TAU)
- Plain-language title
- Tau PET brain scans in memory clinics for mild cognitive impairment and dementiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 18 March 2026